SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, has unveiled new data on a novel approach to chronic pain management and joint tissue preservation. The data highlight SN101, a first-in-class…
Continue Reading
News Source: medicalxpress.com
Leave a Reply